Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemetrexed/Cisplatin followed by Gefitinib vs Pemetrexed/Cisplatin in Asian never-smokers with NSCLC
NCT00409006Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2007
- Primary completion
- Aug 2009
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, open-label trial of pemetrexed and gefitinib in non-small cell lung cancer (NSCLC), sponsored by Eli Lilly and Company. Started Feb 2007; status: completed.
02
Drugs
pemetrexedgefitinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00409006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00409006.